{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:40:35Z","timestamp":1791463235752,"version":"4.3.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>It is not clear whether polymyxin B\/tigecycline (PMB\/TGC) combination is better than PMB or TGC alone in the treatment of hospital-acquired pneumonia (HAP) caused by carbapenem-resistant organisms (CROs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a multicenter, retrospective cohort study in patients with HAP caused by CROs. The primary outcome was 28-day mortality, and the secondary outcomes included clinical success and the incidence of acute kidney injury (AKI). Multivariate Cox regression analysis was performed to examine the relationship between antimicrobial treatments and 28-day mortality by adjusting other potential confounding factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 364 eligible patients were included in the final analysis, i.e., 99 in the PMB group, 173 in the TGC group, and 92 in the PMB\/TGC combination group. The 28-day mortality rate was 28.3% (28\/99) in the PMB group, 39.3% (68\/173) in the TGC group, and 48.9% (45\/92) in the PMB\/TGC combination group (<jats:italic>p<\/jats:italic>= 0.014). The multivariate Cox regression model showed that there was a statistically significant lower risk of 28-day mortality among participants in the PMB group when compared with the PMB\/TGC combination group [hazard ratio (HR) 0.50, 95% confidence interval (CI) 0.31\u20130.81,<jats:italic>p<\/jats:italic>= 0.004] and that participants in the TGC group had a lower risk of 28-day mortality than in the PMB\/TGC combination group but without statistical significance. The incidence of AKI in the PMB group (52.5%) and the PMB\/TGC combination group (53.3%) was significantly higher than that in the TGC group (33.5%,<jats:italic>p<\/jats:italic>= 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The appropriate PMB\/TGC combination was not superior to appropriate PMB therapy in the treatment of HAP caused by carbapenem-resistant<jats:italic>Enterobacteriaceae<\/jats:italic>\/carbapenem-resistant<jats:italic>Acinetobacter baumannii<\/jats:italic>(CRE\/CRAB) in terms of 28-day mortality.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.772372","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T05:37:52Z","timestamp":1654839472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Polymyxin B\/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii"],"prefix":"10.3389","volume":"9","author":[{"given":"Kang","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenshun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanlin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg Infect Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"ofv050","DOI":"10.1093\/ofid\/ofv050","article-title":"Treatment options for carbapenem-resistant Enterobacteriaceae infections.","volume":"2","author":"Morrill","year":"2015","journal-title":"Open Forum Infect Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae.","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1001\/jama.2015.12480","article-title":"Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012\u20132013.","volume":"314","author":"Guh","year":"2015","journal-title":"JAMA."},{"key":"B5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","article-title":"Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.","volume":"75","author":"van Duin","year":"2013","journal-title":"Diagn Microbiol Infect Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"ofx176","DOI":"10.1093\/ofid\/ofx176","article-title":"Prevalence of carbapenem-resistant gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa.","volume":"4","author":"Cai","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1469-0691.2008.02061.x","article-title":"Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies.","volume":"14","author":"Petrosillo","year":"2008","journal-title":"Clin Microbiol Infect."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/jac\/dku168","article-title":"Combination therapy for carbapenem-resistant Gram-negative bacteria.","volume":"69","author":"Paul","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cmi.2018.01.015","article-title":"Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals.","volume":"24","author":"Papst","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000682","article-title":"Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms.","author":"Kois","year":"2020","journal-title":"Curr Opin Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cmi.2017.09.016","article-title":"The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.","volume":"24","author":"Amat","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B14","doi-asserted-by":"publisher","first-page":".e1","DOI":"10.1016\/j.cmi.2017.10.033","article-title":"Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.","volume":"24","author":"Liang","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.","volume":"72","author":"Zusman","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","article-title":"Time to treatment and mortality during mandated emergency care for sepsis.","volume":"376","author":"Seymour","year":"2017","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy."},{"key":"B18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fmicb.2019.00080","article-title":"Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options.","volume":"10","author":"Sheu","year":"2019","journal-title":"Front Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system.","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine.","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med."},{"key":"B22","year":"2020","journal-title":"M100-ED30:2020 Performance Standards for Antimicrobial Susceptibility Testing."},{"key":"B23","year":"2019","journal-title":"Tigecycline \u2013 Injection products."},{"key":"B24","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society.","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1155\/2008\/593289","article-title":"Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.","volume":"19","author":"Rotstein","year":"2008","journal-title":"Can J Infect Dis Med Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.","volume":"17","author":"Gutierrez-Gutierrez","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US Hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents.","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis."},{"key":"B28","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury.","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract."},{"key":"B29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1214243","article-title":"Acute kidney injury and chronic kidney disease as interconnected syndromes.","volume":"371","author":"Chawla","year":"2014","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3).","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA."},{"key":"B31","doi-asserted-by":"publisher","first-page":"O117","DOI":"10.1111\/1469-0691.12341","article-title":"Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options.","volume":"20","author":"Kontopidou","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1097\/CCM.0000000000000933","article-title":"Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study.","volume":"43","author":"Cheng","year":"2015","journal-title":"Crit Care Med."},{"key":"B33","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1128\/AAC.01624-13","article-title":"In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.","volume":"58","author":"Hagihara","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.","volume":"2021","author":"Yaghoubi","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"B36","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1086\/431674","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline.","volume":"5","author":"Meagher","year":"2005","journal-title":"Clin Infect Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2015.08.009","article-title":"Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs.","volume":"39","author":"Shen","year":"2015","journal-title":"Int J Infect Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1086\/648720","article-title":"Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.","volume":"50","author":"Gardiner","year":"2010","journal-title":"Clin Infect Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e3126","DOI":"10.1097\/MD.0000000000003126","article-title":"Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.","volume":"95","author":"Ni","year":"2016","journal-title":"Medicine."},{"key":"B40","year":"2017","journal-title":"FDA Drug Safety Communication: Increased Risk of Death With Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/cid\/cis270","article-title":"Excess deaths associated with tigecycline after approval based on noninferiority trials.","volume":"54","author":"Prasad","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ijantimicag.2013.01.020","article-title":"All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials.","volume":"41","author":"McGovern","year":"2013","journal-title":"Int J Antimicrob Agents."},{"key":"B43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijantimicag.2014.10.002","article-title":"In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis.","volume":"45","author":"Ni","year":"2015","journal-title":"Int J Antimicrob Agents."},{"key":"B44","doi-asserted-by":"publisher","first-page":"533209","DOI":"10.3389\/fmicb.2020.533209","article-title":"In vitro synergistic activity of antimicrobial combinations against and -producing with or mcr genes.","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Microbiol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.12.009","article-title":"Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins.","author":"Wagenlehner","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41564-019-0480-z","article-title":"Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection.","volume":"4","author":"Band","year":"2019","journal-title":"Nat Microbiol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.772372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T21:16:48Z","timestamp":1675804608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.772372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":46,"alternative-id":["10.3389\/fmed.2022.772372"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.772372","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"article-number":"772372"}}